Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous retrovirus group H member 1 (ERVH-1)
- Target
- ERVH-1
- Molecular classification
- Other (specifically, human endogenous retrovirus/LTR retrotransposon), Noncoding RNA (in functional context)
01
Overview
Endogenous retrovirus group H member 1 (ERVH-1 or HERV-H4p15.2) is a human genomic locus derived from ancient retroviral insertions. It belongs to the HERV-H family, characterized by long terminal repeats (LTRs) and sequences analogous to retroviral gag, pol, and env genes, though most protein-coding capacity has been lost. The locus primarily produces noncoding RNAs and functions as a transcriptional regulatory region. Its expression is epigenetically regulated and has been observed to be silenced in colon tumor tissues while being active in the corresponding normal tissues, suggesting a role in the regulatory landscape of cancer biology. While ERVH-1 is not targeted by current therapeutics and does not encode functional proteins, its regulatory activity through noncoding RNA and LTRs may impact host gene expression and epigenetic states
- Other names
- HERV-H4p15.2ERVH-1
02
Mechanism of action
Not applicable, as no drugs target this element.
03
Biological functions
Regulation of gene expression through noncoding RNA and long terminal repeats (LTRs)Epigenetic regulation (expression modulated by DNA methylation and histone deacetylation)May act as a transcriptional regulator in certain cellular contexts
04
Disease associations
Altered expression in multiple cancer types, including colon, stomach, and kidney cancer (downregulated in tumor vs. normal tissues)Possible implication in cancer biology via noncoding RNA or regulatory effects on nearby host genesNo validated roles in inflammation, infection, neurodegenerative, or cardiovascular disorders for this specific locus
05
Safety considerations
None documented specific to ERVH-1; broader concerns about targeting endogenous retroviral elements involve risk of off-target epigenetic or genome regulatory effects, but these are theoretical and not validated for ERVH-1
06
Biomarkers
Expression of noncoding RNA from HERV-H4p15.2 can serve as a potential biomarker for distinguishing tumor from normal colon tissue, with active transcription in nontumorous colon and silencing in tumor samples
Beyond the preview
Go deeper on Endogenous retrovirus group H member 1 (ERVH-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous retrovirus group H member 1 (ERVH-1).